ArticleGene therapy2002
Novel chimeric gene promoters responsive to hypoxia and ionizing radiation.
Article in Gene therapy, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 76 citations in OpenAlex.
- Radiation-Responsive Promoters: Molecular Mechanisms, Screening Strategies, and Translational Applications as Radiation Biomarkers.Current issues in molecular biology · 2026Review
- Systemic Delivery of Magnetogene Nanoparticle Vector for Gene Expression in Hypoxic Tumors.Pharmaceutics · 2023Article
- Cell line development for continuous high cell density biomanufacturing: Exploiting hypoxia for improved productivity.Metabolic engineering communications · 2021Article
- Enzyme prodrug therapy: cytotoxic potential of paracetamol turnover with recombinant horseradish peroxidase.Monatshefte fur chemie · 2021Article
- Friend or foe, the role of EGR-1 in cancer.Medical oncology (Northwood, London, England) · 2019Review
- Intrinsic hypoxia sensitivity of the cytomegalovirus promoter.Cell death & disease · 2015Article
- p53 activated by AND gate genetic circuit under radiation and hypoxia for targeted cancer gene therapy.Cancer science · 2015Article
- Influential Factors and Synergies for Radiation-Gene Therapy on Cancer.Analytical cellular pathology (Amsterdam) · 2015Review
- Article
- Translational regulation of specific mRNAs controls feedback inhibition and survival during macrophage activation.PLoS genetics · 2014Article
- Evaluation of p21 promoter for interleukin 12 radiation induced transcriptional targeting in a mouse tumor model.Molecular cancer · 2013Article
- Therapeutic improvement of a stroma-targeted CRAd by incorporating motives responsive to the melanoma microenvironment.The Journal of investigative dermatology · 2013Article
- An oncolytic adenovirus regulated by a radiation-inducible promoter selectively mediates hSulf-1 gene expression and mutually reinforces antitumor activity of I131-metuximab in hepatocellular carcinoma.Molecular oncology · 2013Article
- The radiation dose-regulated AND gate genetic circuit, a novel targeted and real-time monitoring strategy for cancer gene therapy.Cancer gene therapy · 2012Article
- Translation of the radio- and chemo-inducible TNFerade vector to the treatment of human cancers.Cancer gene therapy · 2009Article
- Suppression of cancer growth by nonviral gene therapy based on a novel reactive oxygen species-responsive promoter.Molecular therapy : the journal of the American Society of Gene Therapy · 2009Article
- Bacterial delivery of a novel cytolysin to hypoxic areas of solid tumors.Gene therapy · 2009Article
- The radiation-inducible pE9 promoter driving inducible nitric oxide synthase radiosensitizes hypoxic tumour cells to radiation.Gene therapy · 2008Article
- Targeted molecular imaging in oncology: focus on radiation therapy.Seminars in radiation oncology · 2008Review
- Radioresponsive tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene therapy for malignant brain tumors.Cancer gene therapy · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite being an adverse prognostic factor in radiotherapy, hypoxia represents a physiological difference that can be exploited for selective cancer gene therapy. In this study gene therapy vectors responsive to both hypoxia and ionizing radiation (IR) were developed. Gene expression was regulated by novel, synthetic promoters containing hypoxia responsive elements (HREs) from the erythropoietin (Epo), the phosphoglycerate kinase 1 (PGK1) and the vascular endothelial growth factor (VEGF) genes, and IR-responsive CArG elements from the early growth response (Egr) 1 gene. All chimeric promoters could be activated by hypoxia and/or IR-treatment, and selectively control marker gene expression in human T24 bladder carcinoma and MCF-7 mammary carcinoma cells. Importantly, enhancers containing combinations of HREs and CArG elements were able to respond to both triggering treatments, with the Epo HRE/CArG combination proving to be the most responsive and robust. The Epo HRE/CArG enhancer could effectively control a suicide gene therapy strategy by selectively sensitizing hypoxic and/or irradiated cells expressing the enzyme horseradish peroxidase (HRP) to the prodrug indole-3-acetic acid (IAA). These data indicate that the use of such chimeric promoters may effectively regulate therapeutic gene expression within the tumor microenvironment in gene therapy strategies aimed at addressing the problem of hypoxia in radiotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.